Dear Health Care Professional letter about the reports of Severe Cutaneous Adverse Reactions associated with the use of the medicinal product Incivo 375 mg, film-coated tablets (telaprevir)
The company Johnson & Johnson S.E. d.o.o., the marketing authorisation holder for the medicinal product Incivo 375 mg, film-coated tablets (telaprevir) has, in collaboration with the Agency for Medicinal Products and Medical Devices (HALMED) sent out a letter to health care professionals about the risk of Severe Cutaneous Adverse Reactions (SCAR), associated with the use of the medicinal product Incivo. The letter reminds health care professionals on the current recommendations for the monitoring and treatment of skin adverse reactions listed in the Summary of Product Characteristics for Incivo 375 mg, film-coated tablets.
You may view the letter in the continuation of this information.